Login to Your Account

Genzyme Acquires Avigen's AAV Assets For $12M, More

By Karen Pihl-Carey

Thursday, December 22, 2005
Eight months after Avigen Inc. decided to stop funding its adeno-associated virus technology, it found a buyer in Genzyme Corp. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription